Tetridar® (teriparatide)

This information is only for patients who have been prescribed Tetridar® (teriparatide)

What is Tetridar®?

Tetridar® contains the active substance teriparatide that is used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation.

What Tetridar® is used for?

Tetridar® is used to treat osteoporosis in adults. Osteoporosis is a disease that causes your bones to become thin and fragile. This disease is especially common in women after the menopause, but it can also occur in men.

Osteoporosis is also common in patients receiving corticosteroids.



Instructions on how to use the Tetridar® (teriparatide) pen: 


Please read your patient information leaflet carefully before you start using this medicine because it contains important information for you, including step by step instructions on how to administer Tetridar®. You should not inject yourself until you have been trained by your doctor or nurse. You should also contact them if you have any further questions.

Further information and support

The patient information leaflet can be downloaded from the HPRA website and you can contact Teva with any question about this medicine that you may have.

Patient Information Leaflet

Download from HPRA

For questions about your medicine contact Teva

Contact us

Life Effects™

Living with one or more chronic conditions affects your life in so many ways. The only people who really know what you are going through are those who have faced the same challenges. With that in mind we have created Life Effects™, an initiative shaped by patients for patients.

Discover more Life Effects™

If you experience any side effects (adverse events), talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience. See www.hpra.ie for how to report side effects. Side effects may also be reported directly to Teva using our online form.

Date of preparation: January 2023
Reference: COB-IE-NP-00044